Overview of Fertility Inc.: The Embryo Editing Dinner
This episode of The Journal (Wall Street Journal & Spotify Studios) investigates a secretive corner of Silicon Valley pushing to use embryo editing—altering an embryo’s DNA to prevent disease or potentially enhance traits—to bring genetically modified babies to term. Reporting centers on a July dinner hosted by Coinbase CEO Brian Armstrong, the emergence of a stealth company called Preventive backed by tech investors (including Sam Altman and Armstrong), and the larger ethical, scientific, and regulatory debate around germline editing versus embryo screening.
Key players & companies
- Brian Armstrong — Coinbase co‑founder and CEO. Hosted the private “embryo editing dinner,” advocated publicly for a “Gattaca stack,” and is an investor in embryo-related ventures.
- Sam Altman — OpenAI CEO. Connected to Preventive via investment (reported that his husband Oliver Mulherin led their investment).
- Preventive — A San Francisco biotech startup (initially in stealth) pursuing research into embryo editing. Reported to have explored working outside the U.S. and to have pitched some scientists; Preventive states it is focused on safety research and not on implanting edited embryos.
- He Jiankui — Chinese scientist who in 2018 claimed to have created the first gene‑edited babies (Lulu and Nana); convicted and jailed in China. His case sparked global condemnation and heightened scrutiny.
- Orchid and Nucleus — Startups offering advanced embryo screening (Orchid focuses on disease risk profiling; Nucleus advertises a wide range of trait predictions, including height and intelligence). Screening is legal in the U.S., and some tests claim to be laboratory-developed and outside FDA review.
What the WSJ reporting found
- A private dinner at upscale San Francisco restaurant Quince convened wealthy tech figures and scientists to discuss bringing embryo editing to fruition. The calendar invite reportedly labeled it an “embryo editing dinner.”
- Attendees discussed both disease-prevention edits and “enhancements” (e.g., stronger bones, lower cholesterol, possibly traits like height or hair). A controversial idea surfaced about secretly developing and then revealing a healthy genetically engineered baby to force public acceptance; Armstrong’s spokespeople downplayed his support for that tactic.
- Journal reporters uncovered Preventive via filings and LinkedIn hires. They confirmed investments by Armstrong and Altman (amounts undisclosed). Reporting suggested Preventive had researched jurisdictions outside the U.S. (e.g., UAE) and had spoken with prospective parents and scientists.
- Preventive denies having identified or worked with a couple on embryo editing and describes its work as safety research; despite criticism, it has continued hiring scientists.
Scientific and ethical concerns
- Heritability: Edits to embryos are germline changes that pass to future generations. Off-target effects or unintended consequences could propagate through descendants.
- Safety: Current consensus among many researchers is that embryo editing is not sufficiently safe or well understood for clinical application to produce live births.
- Societal risk: Beyond therapy, edits could be used for enhancements—so‑called “designer babies”—raising fears of widening inequality, new forms of eugenics, and societal bifurcation.
- Regulatory and normative resistance: Prominent scientists and ethicists called for a 10‑year moratorium (as recently as 2025 in the episode) on bringing edited embryos to term until global frameworks are in place.
Regulation and legal status
- Many countries ban or restrict germline editing intended to establish a pregnancy. In the U.S., the FDA cannot review clinical trial applications involving pregnancies from edited embryos.
- The lack of uniform global regulation incentivizes actors to consider conducting work in jurisdictions with looser oversight (the episode mentions the UAE as an example).
- Embryo screening (non‑editing) is legal in the U.S. and widely offered, although its accuracy, claims, and ethical boundaries are contested.
Embryo screening vs embryo editing
- Screening: Tests embryos for genetic risks/traits, then selects which embryo to implant. Legal and increasingly comprehensive (disease risks, complex traits). Examples: Orchid (disease risk profiling, ~$2,500/embryo), Nucleus (broader trait insights, starting ~$10,000).
- Editing: Alters embryo DNA directly to change traits or prevent disease; potentially heritable and much more ethically fraught. Editing is technically more complex and currently restricted.
- The episode argues tech capital is funding both approaches; screening may be easier to deploy and could achieve many of the same social outcomes (selection of traits) without genetic modification.
Notable quotes & framing
- Armstrong (on X after reporting): invested in Preventive and framed gene editing as a way to help the ~300 million people living with genetic disease.
- The episode repeatedly invokes Gattaca (the film) as a cultural touchstone for fears about a future where embryos are designed or selected to produce “better” humans.
Main takeaways
- There is a real, well‑funded push from parts of Silicon Valley to accelerate embryo editing research and potentially clinical application, with Preventive as a focal example.
- The debate is not purely scientific but deeply ethical and political: safety, intergenerational risk, equity, and the specter of enhancement/eugenics are central concerns.
- Embryo screening is legal and expanding rapidly, and may produce similar societal outcomes (selection for traits) before editing becomes clinically feasible or acceptable.
- Regulatory gaps and differing international stances create incentives for actors to relocate research or clinical efforts to permissive jurisdictions.
Recommended implications/actions (policy, science, public)
- For policymakers: develop coordinated international frameworks or agreements to govern germline editing, reduce incentives for jurisdiction shopping, and clarify oversight of advanced embryo screening.
- For scientific community: maintain transparent standards, strengthen peer review and governance, and continue to advocate for moratoria or strict criteria for any human applications until safety and ethics are settled.
- For the public: stay informed about the distinctions between screening and editing, and engage in civic conversations about acceptable uses, equity, and long‑term societal impacts.
Conclusion
The episode exposes a clash of cultures—Silicon Valley’s urgency and capital meeting the cautionary norms of medicine and bioethics—centered on an issue with profound implications for individuals and society. Whether through direct editing or expanding screening, the technology to shape future generations is moving from speculative fiction toward real commercial and clinical choices that regulators, scientists, and the public must confront.